Please assess the completion status of the following clinical trial:

Trial Title: SP16 as a Therapeutic for COVID-19 Induced ARDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~To be considered eligible to participate in this study, the subject must meet all of the Inclusion criteria listed below:~* Hospitalized patients age ≥ 18 with diagnosis of SARS-CoV-2-infection based on positive~* PCR test result and can provide informed consent~* Diagnosed with pneumonia due to SARS-CoV-2~* Respiratory rate ≥ 25/minute and SpO2 ≤ 93%~* Review of Chest radiograph, chest computed tomography (CT) scan, or chest ultrasound consistent with bilateral infiltrates.~* Horowitz index (partial pressure of oxygen/fraction of inspired oxygen \[PaO2/FiO2\]) ≤ 300. If a subject does not have an arterial line in place, a SpO2/FiO2 ≤ 315 may be used.~Exclusion Criteria:~To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below:~* Age \< 18~* Pregnant or lactating women~* History of heart failure~* Clinically significant cardiac dysrhythmia, as determined by investigator~* History renal impairment~* Presence of any of the following abnormal laboratory values at screening: absolute neutrophil count (ANC) less than 2000 mm3, aspartate aminotransferase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort dose 1 of SP16 (Type: EXPERIMENTAL): Patients in cohort 1 (low dose SP16) will receive a single dose of SP16 (0.1 mg/kg or 6 mg) by subcutaneous injection
- Cohort dose 2 of SP16 (Type: EXPERIMENTAL): Patients in cohort 2 (high dose SP16) will receive a single dose of SP16 (0.2 mg/kg or 12 mg) by subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Patients in placebo arm will receive sterile water by subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).